Interchangeability among carbamazepine formulations: the impact over epilepsy patients

Abstract The treatment of epilepsy is complex and a matter of concern is the interchangeability among different formulations available for antiepileptic drugs. To evaluate the effects of interchangeability among carbamazepine formulations on patients with epilepsy. This is a prospective cohort study that included adult outpatients diagnosed with epilepsy and under pharmacological treatment with carbamazepine. Before switching the brand/manufacturer, the “Interchangeable Pharmaceutical Product in the Treatment of Epilepsies” questionnaire was applied. The questionnaires “Adverse Events Profile” and Quality of Life in Epilepsy-31, so as the plasma carbamazepine concentrations, were evaluated before and after the brand/ manufacturer switch. Physical-chemical tests aiming to assess tablets quality were performed in accordance with the Brazilian Pharmacopoeia 5th edition. The study population was composed by 14 patients (mean age: 44.6 years), with 10 of females. From those interviewed, 10 had no knowledge about the three antiepileptic drugs formulations available. The frequency of adverse event “problems with skin” incresead (p=0.023) and “upset stomach” decreased (p=0.041) after the changeover. The adverse events profile was associated with only two quality of life domains: “energy/fatigue” (p=0.048) and “total score” (p=0.018). Divergent results between generic and reference formulations were observed in purity-water test (reference: 1.96%, generic: 4.84%) and dissolution test, in which the generic formulation presented 66.27 to 85.77% of carbamazepine dissolved after the third level. Conclusions: Objective differences before and after the brand/manufacturer switch were not observed, in spite of patients’ perceptions. Despite that, more studies in the field are necessary, especially on the interchangeability among generic antiepileptics, in order to better elucidate switching consequences on patients’ life.

Saved in:
Bibliographic Details
Main Authors: Frade,Virgínia Paula, Paiva,Maria José Nunes de, Martins,Isarita, Castro,Whocely Victor de, Belo,Vinícius Silva, Baldoni,André Oliveira, Lima,Priscila de Freitas, Sanches,Cristina
Format: Digital revista
Language:English
Published: Universidade de São Paulo, Faculdade de Ciências Farmacêuticas 2022
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100620
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1984-82502022000100620
record_format ojs
spelling oai:scielo:S1984-825020220001006202022-06-28Interchangeability among carbamazepine formulations: the impact over epilepsy patientsFrade,Virgínia PaulaPaiva,Maria José Nunes deMartins,IsaritaCastro,Whocely Victor deBelo,Vinícius SilvaBaldoni,André OliveiraLima,Priscila de FreitasSanches,Cristina Antiepilepticdrugs Carbamazepine Epilepsy Genericmedications Interchangeability Abstract The treatment of epilepsy is complex and a matter of concern is the interchangeability among different formulations available for antiepileptic drugs. To evaluate the effects of interchangeability among carbamazepine formulations on patients with epilepsy. This is a prospective cohort study that included adult outpatients diagnosed with epilepsy and under pharmacological treatment with carbamazepine. Before switching the brand/manufacturer, the “Interchangeable Pharmaceutical Product in the Treatment of Epilepsies” questionnaire was applied. The questionnaires “Adverse Events Profile” and Quality of Life in Epilepsy-31, so as the plasma carbamazepine concentrations, were evaluated before and after the brand/ manufacturer switch. Physical-chemical tests aiming to assess tablets quality were performed in accordance with the Brazilian Pharmacopoeia 5th edition. The study population was composed by 14 patients (mean age: 44.6 years), with 10 of females. From those interviewed, 10 had no knowledge about the three antiepileptic drugs formulations available. The frequency of adverse event “problems with skin” incresead (p=0.023) and “upset stomach” decreased (p=0.041) after the changeover. The adverse events profile was associated with only two quality of life domains: “energy/fatigue” (p=0.048) and “total score” (p=0.018). Divergent results between generic and reference formulations were observed in purity-water test (reference: 1.96%, generic: 4.84%) and dissolution test, in which the generic formulation presented 66.27 to 85.77% of carbamazepine dissolved after the third level. Conclusions: Objective differences before and after the brand/manufacturer switch were not observed, in spite of patients’ perceptions. Despite that, more studies in the field are necessary, especially on the interchangeability among generic antiepileptics, in order to better elucidate switching consequences on patients’ life.info:eu-repo/semantics/openAccessUniversidade de São Paulo, Faculdade de Ciências FarmacêuticasBrazilian Journal of Pharmaceutical Sciences v.58 20222022-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100620en10.1590/s2175-97902022e19594
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Frade,Virgínia Paula
Paiva,Maria José Nunes de
Martins,Isarita
Castro,Whocely Victor de
Belo,Vinícius Silva
Baldoni,André Oliveira
Lima,Priscila de Freitas
Sanches,Cristina
spellingShingle Frade,Virgínia Paula
Paiva,Maria José Nunes de
Martins,Isarita
Castro,Whocely Victor de
Belo,Vinícius Silva
Baldoni,André Oliveira
Lima,Priscila de Freitas
Sanches,Cristina
Interchangeability among carbamazepine formulations: the impact over epilepsy patients
author_facet Frade,Virgínia Paula
Paiva,Maria José Nunes de
Martins,Isarita
Castro,Whocely Victor de
Belo,Vinícius Silva
Baldoni,André Oliveira
Lima,Priscila de Freitas
Sanches,Cristina
author_sort Frade,Virgínia Paula
title Interchangeability among carbamazepine formulations: the impact over epilepsy patients
title_short Interchangeability among carbamazepine formulations: the impact over epilepsy patients
title_full Interchangeability among carbamazepine formulations: the impact over epilepsy patients
title_fullStr Interchangeability among carbamazepine formulations: the impact over epilepsy patients
title_full_unstemmed Interchangeability among carbamazepine formulations: the impact over epilepsy patients
title_sort interchangeability among carbamazepine formulations: the impact over epilepsy patients
description Abstract The treatment of epilepsy is complex and a matter of concern is the interchangeability among different formulations available for antiepileptic drugs. To evaluate the effects of interchangeability among carbamazepine formulations on patients with epilepsy. This is a prospective cohort study that included adult outpatients diagnosed with epilepsy and under pharmacological treatment with carbamazepine. Before switching the brand/manufacturer, the “Interchangeable Pharmaceutical Product in the Treatment of Epilepsies” questionnaire was applied. The questionnaires “Adverse Events Profile” and Quality of Life in Epilepsy-31, so as the plasma carbamazepine concentrations, were evaluated before and after the brand/ manufacturer switch. Physical-chemical tests aiming to assess tablets quality were performed in accordance with the Brazilian Pharmacopoeia 5th edition. The study population was composed by 14 patients (mean age: 44.6 years), with 10 of females. From those interviewed, 10 had no knowledge about the three antiepileptic drugs formulations available. The frequency of adverse event “problems with skin” incresead (p=0.023) and “upset stomach” decreased (p=0.041) after the changeover. The adverse events profile was associated with only two quality of life domains: “energy/fatigue” (p=0.048) and “total score” (p=0.018). Divergent results between generic and reference formulations were observed in purity-water test (reference: 1.96%, generic: 4.84%) and dissolution test, in which the generic formulation presented 66.27 to 85.77% of carbamazepine dissolved after the third level. Conclusions: Objective differences before and after the brand/manufacturer switch were not observed, in spite of patients’ perceptions. Despite that, more studies in the field are necessary, especially on the interchangeability among generic antiepileptics, in order to better elucidate switching consequences on patients’ life.
publisher Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
publishDate 2022
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100620
work_keys_str_mv AT fradevirginiapaula interchangeabilityamongcarbamazepineformulationstheimpactoverepilepsypatients
AT paivamariajosenunesde interchangeabilityamongcarbamazepineformulationstheimpactoverepilepsypatients
AT martinsisarita interchangeabilityamongcarbamazepineformulationstheimpactoverepilepsypatients
AT castrowhocelyvictorde interchangeabilityamongcarbamazepineformulationstheimpactoverepilepsypatients
AT beloviniciussilva interchangeabilityamongcarbamazepineformulationstheimpactoverepilepsypatients
AT baldoniandreoliveira interchangeabilityamongcarbamazepineformulationstheimpactoverepilepsypatients
AT limaprisciladefreitas interchangeabilityamongcarbamazepineformulationstheimpactoverepilepsypatients
AT sanchescristina interchangeabilityamongcarbamazepineformulationstheimpactoverepilepsypatients
_version_ 1756437909671510016